Martin Barrett on Intravenous Versus Subcutaneous Rituximab

Video

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

In this study, the standard dose of IV rituximab was concentrated 12 fold, to 120 mg/ml and mixed with a naturally occurring enzyme which allows it to be injected at volumes that would otherwise be difficult to administer, says Barrett.

The injection takes only six minutes, compared with a two to four hour infusion. Complete and overall response rates and toxicity were comparable between the two administration methods.

<<<

View more from the 13th International Conference on Malignant Lymphoma

Related Videos
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania